GHRH analog
Tesamorelin
Also known as Egrifta
FDA-approved drugA growth-hormone-releasing hormone analog with a narrow FDA approval.
Evidence
FDA-approved drug
Regulatory status
Prescription drug. FDA-approved for one specific indication.
Class
GHRH analog
What it is
Tesamorelin is a synthetic version of growth-hormone-releasing hormone (GHRH). It signals the pituitary gland to release the body’s own growth hormone.
What the research shows
- FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.
- Human trials measured changes in visceral (abdominal) fat; research in other populations is more limited.
Read the published research on PubMed →
Researched for
Tesamorelin is a prescription medicine approved only for specific uses. A licensed provider decides whether it is appropriate for you.
Educational content, not medical advice. This page does not recommend or dose any substance.
Related peptides
GLP-1 receptor agonist
Semaglutide
A GLP-1 receptor agonist and one of the most studied peptide medicines in the world.
FDA-approved drugDual GIP / GLP-1 receptor agonistTirzepatide
The first approved medicine that activates both the GIP and GLP-1 receptors.
FDA-approved drugTriple GIP / GLP-1 / glucagon receptor agonistRetatrutide
An investigational "triple agonist" currently in late-stage clinical trials.
Human clinical trials